Loading...
XNAS
PHIO
Market cap12mUSD
Jul 10, Last price  
1.02USD
Name

Phio Pharmaceuticals Corp

Chart & Performance

D1W1MN
XNAS:PHIO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
169.07%
Rev. gr., 5y
-7.79%
Revenues
0k
097,000399,00071,00034,00019,00015,000138,00021,000000000
Net income
-9m
L+21.65%
-10,219,000-12,880,000-20,925,000-8,800,000-10,223,000-8,994,000-12,452,000-7,360,000-8,908,000-8,794,000-13,287,000-11,480,000-10,826,000-7,150,000-8,698,000
CFO
-8m
L+12.19%
-9,989,000-5,062,000-6,311,000-7,758,000-7,317,000-7,760,000-9,514,000-7,520,000-8,645,000-8,802,000-11,858,000-12,129,000-10,749,000-7,112,000-7,979,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
URL
https://phiopharma.com/
IPO date
May 10, 2012
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT